🏛️ Verified NIH Record • Updated 2026-05-28
Timed Aspirin Chronobiome Study (NCT03590821)
🟡 Not Yet Recruiting Early Phase1 💊 Investigational Drug / Biologic Sponsor: University of Pennsylvania
🩺 Plain-English Summary (8th-Grade Level)
To determine whether timed administration of aspirin ameliorates the effects of celecoxib on blood pressure.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (12 items) and avoid the listed exclusions (23 items).
Location: Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania — Philadelphia, Pennsylvania
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Female subjects who are pregnant or nursing a child.
- Subjects who have received an investigational drug or used an experimental medical device within 30 days prior to screening, or who gave a blood donation of ≥ one pint within 8 weeks prior to screening.
- Subjects with any coagulation, bleeding or blood disorders.
- Subjects who are sensitive or allergic to celecoxib (Celebrex) or aspirin or their components.
- Subjects who are sensitive or allergic to aspirin or other NSAIDs.
- Subjects with documented history of any gastrointestinal disorders, including bleeding ulcers.
- History of significant cardiovascular disease (including stroke or TIA), renal, hepatic, respiratory (except infections which longer \> 6 months prior to screening), immune, endocrine, hematopoietic disorder or neurological disorders.
- History of cancer within the last 5 years (except for cutaneous basal cell or squamous cell cancer resolved by excision, or carcinoma in situ of the cervix adequately treated).
- Has taken any prescription medication other than hormone replacement therapy (including males taking testosterone as a hormone replacement to treat a documented low testosterone level), thyroid replacement hormones, anti-hyperlipidemic agents, or anti-hypertensive medications. Individuals taking other/additional chronic stable medications can be considered on a case-by-case basis for inclusion in the study if agreed upon by judgment of the investigators.
- Has taken the following NSAID or antisecretory agents within 2 weeks prior to study drug administration:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) including acetaminophen or other medications for pain, including aspirin or aspirin-containing products
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania — Philadelphia, Pennsylvania
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.